// App-Quantinova.ai

e13539 : Phase II study evaluating the effect of concomitant ramucirumab (IMC-1121B; RAM) on the pharmacokinetics (PK) of docetaxel (DOC) in patients (pts) with advanced malignant solid tumors.

Researchers

Presenter

  • Mark N. Stein

Principal Investigators

  • Laura Quan Man Chow

  • John D. Powderly

  • Ling Gao

  • Yong Lin

  • Minori Koshiji

  • David C. Smith

  • Dale Randall Shepard

  • Ding Wang

Medical Centers

  • Carolina BioOncology Institute, Huntersville, NC

  • ImClone Systems, a wholly-owned subsidiary of Eli Lilly and Company, Bridgewater, NJCleveland Clinic Taussig Cancer Institute, Cleveland, OHImClone Systems, a wholly owned subsidiary of Eli Lilly & Co., Bridgewater, NJ

  • University of Washington, Seattle, WA

  • Eli Lilly and Company, Indianapolis, IN

  • Rutgers Cancer Institute of New Jersey, New Brunswick, NJ

  • University of Michigan Comprehensive Cancer Center, Ann Arbor, MI

  • Josephine Ford Cancer Institute, Henry Ford Health System, Detroit, MI

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Solid malignancies

Biomarkers

  • N/A

Drug/Treatment

  • Ramucirumab

  • Docetaxel

Outcome

  • Positive

Study Design

  • drug-drug interaction

  • pharmacokinetics

Phase

  • II

Study Id's

  • NCT01567163

Sponsors

  • Eli Lilly and Company

  • Eli Lilly and Company

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved